Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

October 11, 2021 12:00 pm Published by Leave your thoughts

– Data add to the growing body of clinical and scientific evidence demonstrating the therapeutic potential of Aramchol, a stearoyl CoA desaturase (SCD 1) down regulator, for the treatment of NASH and Fibrosis

Categorised in:

This post was written by admin

Leave a Reply

Your email address will not be published.